Women’s Health & OB/GYN News

Bulk ordering and text messaging outreach significantly increased completion rates for mammography breast cancer screening, according to results of two randomized clinical trials published in JAMA Internal Medicine.

Having a primary care provider raises the likelihood of being up to date on cervical cancer screening, regardless of sexual orientation, but the association was greatest among lesbian, gay and bisexual women, according to researchers.

Premature surgical menopause may increase the likelihood of musculoskeletal discomfort and sarcopenia, highlighting the potential importance of hormones in postmenopausal musculoskeletal health, researchers reported in Menopause.

Same-day start contraception was common and associated with a low pregnancy risk during the first month of initiation, regardless of emergency contraception use or recent unprotected intercourse, researchers reported.

High adherence to an antioxidant diet reduced the risk for acne impacting patient quality of life in women, according to a study.

Children conceived via fresh or frozen embryo transfer may have increased risk for acute lymphoblastic leukemia compared with children conceived naturally, according to cohort study results published in JAMA Network Open.

The Eat, Sleep, Console approach — which prioritizes nonpharmacologic care — improved outcomes among infants treated for opioid withdrawal syndrome, according to study results published in JAMA Pediatrics.

A greater proportion of American Indian or Alaska Native and Black women of reproductive age live in states with effective abortion bans vs. limited or available access, highlighting possible unequal impact of abortion bans, data show.

BOSTON — Although legislative restrictions make it challenging to prescribe medication abortion, “it is definitely possible” for internal medicine physicians to do, Cynthia H. Chuang, MD, MSc, FACP, said at the ACP Internal Medicine Meeting.

The FDA has approved trastuzumab-strf as a biosimilar to trastuzumab for the treatment of certain patients with HER2-overexpressing malignancies, according to a press release from the agent’s manufacturer.